Vir Biotechnology annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Vir Biotechnology Debt-to-Equity Ratio Growth & History (VIR)
Vir Biotechnology's debt-to-equity ratio was 0.13 for fiscal 2025.
View full Vir Biotechnology company overviewVir Biotechnology annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.13 | 0.04 | +50.26% |
| 2024 | 2024-12-31 | 0.09 | 0.01 | +8.66% |
| 2023 | 2023-12-31 | 0.08 | 0.02 | +27.16% |
| 2022 | 2022-12-31 | 0.06 | −0.03 | −35.86% |
| 2021 | 2021-12-31 | 0.10 | −0.00 | −3.25% |
| 2020 | 2020-12-31 | 0.10 | 0.10 | +3600.56% |
| 2019 | 2019-12-31 | 0.00 | — | — |
Vir Biotechnology quarterly debt-to-equity ratio
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.09 | −0.01 | −12.01% |
| Q1 2026 | 2026-03-31 | 0.12 | 0.03 | +27.74% |
| Q4 2025 | 2025-12-31 | 0.13 | 0.04 | +50.26% |
| Q3 2025 | 2025-09-30 | 0.13 | 0.03 | +38.39% |
| Q2 2025 | 2025-06-30 | 0.11 | 0.03 | +35.08% |
| Q1 2025 | 2025-03-31 | 0.09 | 0.01 | +17.65% |
| Q4 2024 | 2024-12-31 | 0.09 | 0.01 | +8.66% |
| Q3 2024 | 2024-09-30 | 0.09 | 0.01 | +19.29% |
| Q2 2024 | 2024-06-30 | 0.08 | 0.01 | +10.08% |
| Q1 2024 | 2024-03-31 | 0.08 | 0.01 | +19.80% |
| Q4 2023 | 2023-12-31 | 0.08 | 0.02 | +27.16% |
| Q3 2023 | 2023-09-30 | 0.08 | 0.02 | +25.03% |
| Q2 2023 | 2023-06-30 | 0.07 | 0.00 | +5.46% |
| Q1 2023 | 2023-03-31 | 0.07 | −0.00 | −4.51% |
| Q4 2022 | 2022-12-31 | 0.06 | −0.03 | −35.86% |
| Q3 2022 | 2022-09-30 | 0.06 | −0.02 | −25.97% |
| Q2 2022 | 2022-06-30 | 0.07 | −0.03 | −29.99% |
| Q1 2022 | 2022-03-31 | 0.07 | −0.04 | −36.55% |
| Q4 2021 | 2021-12-31 | 0.10 | −0.00 | −3.25% |
| Q3 2021 | 2021-09-30 | 0.08 | 0.06 | +305.32% |
| Q2 2021 | 2021-06-30 | 0.10 | 0.07 | +226.99% |
| Q1 2021 | 2021-03-31 | 0.11 | 0.06 | +131.20% |
| Q4 2020 | 2020-12-31 | 0.10 | 0.10 | +3600.56% |
| Q3 2020 | 2020-09-30 | 0.02 | — | — |
| Q2 2020 | 2020-06-30 | 0.03 | — | — |
| Q1 2020 | 2020-03-31 | 0.05 | — | — |
| Q4 2019 | 2019-12-31 | 0.00 | — | — |
Vir Biotechnology debt-to-equity ratio trends
Over the last five fiscal years, Vir Biotechnology's debt-to-equity ratio increased from 0.10 to 0.13, a change of 0.03. The latest reported quarter, Q2 2026, shows 0.09.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vir Biotechnology source filings ↗